Are you over 18 and want to see adult content?
More Annotations
A complete backup of annmariegianni.com
Are you over 18 and want to see adult content?
A complete backup of growthsupply.com
Are you over 18 and want to see adult content?
A complete backup of payspacemagazine.com
Are you over 18 and want to see adult content?
A complete backup of andrews-sykes.com
Are you over 18 and want to see adult content?
A complete backup of studentloansherpa.com
Are you over 18 and want to see adult content?
A complete backup of skipthegames.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of xn--12clet5dg8bobg4nqbzb7hm.com
Are you over 18 and want to see adult content?
A complete backup of muellerspasta.com
Are you over 18 and want to see adult content?
A complete backup of climatestotravel.com
Are you over 18 and want to see adult content?
A complete backup of menstrength-manuals.pw
Are you over 18 and want to see adult content?
A complete backup of howsyourhearing.org
Are you over 18 and want to see adult content?
Text
source when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system.VIGIFLOW
Vigiflow
UMC | UPPSALA MONITORING CENTREGLOBAL PHARMACOVIGILANCERESEARCH & SCIENTIFIC DEVELOPMENTEDUCATION & TRAININGWHODRUG Making medicines safer for patients. Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace. Our story. UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system.VIGIFLOW
Vigiflow
UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. UMC | WHODRUG NEWSLETTER 2021 We make your experience more interactive. Simply follow the link below to open the WHODrug Newsletter in your web browser: you can choose now whether to subscribe to our Newsletter, translate its content or read past issues. March 1st, 2021. WHODrug Newsletter, March issue 2021.UMC | ACCESS TOOLS
Depending on your level of access click on the links below for the tools and services you need: WHODrug Insight Change Request WHODrug Koda Change Analysis Licence validation. For access managers and WHODrug delivery persons: WHODrug Access Manager WHODrug Files Download. In our User Area you will find User Guides, VersionVerifications
UMC | WHODRUG KODA
WHODrug Koda – the coding engine. WHODrug Koda is an automated coding service custom-built by UMC. The service is specifically designed for increasing the efficiency, consistency and quality of drug coding, with the end goal of safer use of medicines. UMC recognises that the vital activity of drug coding can be both challenging and timeUMC | WHODRUG CAT
The WHODrug Change Analysis Tool (CAT) facilitates up-versioning of WHODrug. This web-based tool will give the user a complete, clear and easy-to-understand overview of dictionary changes, displayed in straightforward detail, record by record. A summary of the data-changes is provided, facilitating internal communication andunderstanding of
UMC | UPGRADING FROM WHODRUG ENHANCED TO WHODRUG GLOBAL WHODrug Enhanced was introduced in 2005 and mainly provided WHODrug users with information on non-herbal medications. The dictionary has now been discontinued and replaced by WHODrug Global. Older versions of WHODrug Enhanced will still be available to users, with the last release being 1 September 2020.UMC | TRAINING
We develop and update our products with input and ideas that come directly from conversations with our customers. We discuss your wishes and requirements and do our utmost to bring you the solutions you want. We know you are busy, so we have developed a range of education and training opportunities to suit your schedule. UMC | ANALYTICS IN VIGILYZE IC stands for “ information component ”, which is an indicator value for disproportionate reporting when using the method for disproportionality analysis developed by UMC. As with the EBGM, PRR or ROR, this is a way to relate observed and expected values to find drug–adverse effect combinations that have been reported more oftenthan one
UMC | LICENSE VALIDATION SERVICE WHODrug License Validation is a mandatory procedure that confirms the WHODrug license status of an intended collaborating partner. An organisation is not allowed to provide a partner organisation with WHODrug data or parts thereof before UMC has confirmed the existence of a valid license. WHODrug users are invited to use UMC’s web-based UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance. UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
VIGIFLOW
Vigiflow
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance. UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
VIGIFLOW
Vigiflow
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | COVID-19
Pharmacovigilance and COVID-19 . O ur work as a global community of pharmacovigilance professionals is more important than ever. As the medical and scientific community work tirelessly to find suitable treatments for COVID-19, the efforts of the WHO Programme for International Drug Monitoring and other pharmacovigilance stakeholders are vital to the success of public health initiatives across UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | HOW TO REPORT ICSRS FOR COVID-19 TREATMENTS results of tests and procedures. cause of death (if applicable) narrative, sender’s diagnosis, and sender’s comments. When treatment is given as part of an approved clinical trial for COVID-19, appropriate fields should be used to indicate this noting the study name and study number. The report type should also indicate Reportfrom study.
UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
UMC | MEDSAFETYWEEK
About the campaign. During the annual #MedSafetyWeek, Uppsala Monitoring Centre teams up with medicine regulators around the world to encourage reporting of side effects. The next campaign will run on 1–7 November 2021 and the theme will be vaccine safety. UMC | COLLABORATIONS We value collaborations. As in much successful scientific research, collaborations in pharmacovigilance bring together the diverse strengths of individuals and organisations to find solutions to complex problems. UMC staff greatly value such opportunities. The research team has long worked across national and regional borders in multi-disciplinary scientific projects, while colleagues from UMC | UPGRADING FROM WHODRUG ENHANCED TO WHODRUG GLOBAL WHODrug Enhanced was introduced in 2005 and mainly provided WHODrug users with information on non-herbal medications. The dictionary has now been discontinued and replaced by WHODrug Global. Older versions of WHODrug Enhanced will still be available to users, with the last release being 1 September 2020. UMC | WHODRUG VENDOR PROGRAMME The WHODrug Vendor Programme provides system and service developers with unique insights into the WHODrug data for a successful implementation of WHODrug Global within software systems. The WHODrug Vendor Programme is currently available for organisations considering supporting WHODrug Global with one of the following types of softwaresystems
UMC | COMMUNICATING SIGNALS Communicating signals. UMC communicates signals of suspected medicines safety problems to national pharmacovigilance centres via VigiLyze, and subsequently to the wider world via WHO Pharmaceuticals Newsletter. Signals are based on information derived from individual case safety reports in VigiBase . UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance. UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
VIGIFLOW
Vigiflow
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance. UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
VIGIFLOW
Vigiflow
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | COVID-19
Pharmacovigilance and COVID-19 . O ur work as a global community of pharmacovigilance professionals is more important than ever. As the medical and scientific community work tirelessly to find suitable treatments for COVID-19, the efforts of the WHO Programme for International Drug Monitoring and other pharmacovigilance stakeholders are vital to the success of public health initiatives across UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | HOW TO REPORT ICSRS FOR COVID-19 TREATMENTS results of tests and procedures. cause of death (if applicable) narrative, sender’s diagnosis, and sender’s comments. When treatment is given as part of an approved clinical trial for COVID-19, appropriate fields should be used to indicate this noting the study name and study number. The report type should also indicate Reportfrom study.
UMC | WHODRUG USER AREA What we offer. Here you will find user and best practice guides, and information about past and upcoming user group meetings, as well as documents to assist you in your daily work with WHODrug. Monthly webinar sessions are held and posted in the WHODrug User Area; recorded sessions together with slides are available and provide youwith unique
UMC | MEDSAFETYWEEK
About the campaign. During the annual #MedSafetyWeek, Uppsala Monitoring Centre teams up with medicine regulators around the world to encourage reporting of side effects. The next campaign will run on 1–7 November 2021 and the theme will be vaccine safety. UMC | COLLABORATIONS We value collaborations. As in much successful scientific research, collaborations in pharmacovigilance bring together the diverse strengths of individuals and organisations to find solutions to complex problems. UMC staff greatly value such opportunities. The research team has long worked across national and regional borders in multi-disciplinary scientific projects, while colleagues from UMC | UPGRADING FROM WHODRUG ENHANCED TO WHODRUG GLOBAL WHODrug Enhanced was introduced in 2005 and mainly provided WHODrug users with information on non-herbal medications. The dictionary has now been discontinued and replaced by WHODrug Global. Older versions of WHODrug Enhanced will still be available to users, with the last release being 1 September 2020. UMC | WHODRUG VENDOR PROGRAMME The WHODrug Vendor Programme provides system and service developers with unique insights into the WHODrug data for a successful implementation of WHODrug Global within software systems. The WHODrug Vendor Programme is currently available for organisations considering supporting WHODrug Global with one of the following types of softwaresystems
UMC | COMMUNICATING SIGNALS Communicating signals. UMC communicates signals of suspected medicines safety problems to national pharmacovigilance centres via VigiLyze, and subsequently to the wider world via WHO Pharmaceuticals Newsletter. Signals are based on information derived from individual case safety reports in VigiBase . UMC | UPPSALA MONITORING CENTREGLOBAL PHARMACOVIGILANCERESEARCH & SCIENTIFIC DEVELOPMENTEDUCATION & TRAININGWHODRUG Making medicines safer for patients. Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace. Our story. UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identifiedUMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | KNOW MORE ABOUT VIGIBASE As well as member countries of the WHO Programme, VigiBase can be made available to anyone with a health profession degree (physician, dentist, nurse, pharmacist). If you request data, please state the purpose of your request. Each request is assessed as a securitymeasure to
UMC | ANALYTICS IN VIGILYZE IC stands for “ information component ”, which is an indicator value for disproportionate reporting when using the method for disproportionality analysis developed by UMC. As with the EBGM, PRR or ROR, this is a way to relate observed and expected values to find drug–adverse effect combinations that have been reported more oftenthan one
VIGIFLOW
Vigiflow
UMC | UPPSALA MONITORING CENTREGLOBAL PHARMACOVIGILANCERESEARCH & SCIENTIFIC DEVELOPMENTEDUCATION & TRAININGWHODRUG Making medicines safer for patients. Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace. Our story. UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identifiedUMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | KNOW MORE ABOUT VIGIBASE As well as member countries of the WHO Programme, VigiBase can be made available to anyone with a health profession degree (physician, dentist, nurse, pharmacist). If you request data, please state the purpose of your request. Each request is assessed as a securitymeasure to
UMC | ANALYTICS IN VIGILYZE IC stands for “ information component ”, which is an indicator value for disproportionate reporting when using the method for disproportionality analysis developed by UMC. As with the EBGM, PRR or ROR, this is a way to relate observed and expected values to find drug–adverse effect combinations that have been reported more oftenthan one
VIGIFLOW
Vigiflow
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | SERVICES
VigiBase Custom Searches. For professional colleagues, UMC offers custom searches of VigiBase data. Let us know the purpose of your request and your search criteria, and we will help you find the information or the solution. A consultancy fee is charged for the service, which is waived for WHO Programme members. More about customsearches.
UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | E-LEARNING IN PHARMACOVIGILANCE Introduction to pharmacovigilance. 30 min (1 module) Audio: English, Spanish. Subtitles: English, Spanish. Pharmacovigilance is needed to address the limitations of clinical trials and the burden of adverse drug reactions on patients and health systems. This course introduces the aim, scope, and history of pharmacovigilance.UMC | ACCESS TOOLS
Depending on your level of access click on the links below for the tools and services you need: WHODrug Insight Change Request WHODrug Koda Change Analysis Licence validation. For access managers and WHODrug delivery persons: WHODrug Access Manager WHODrug Files Download. In our User Area you will find User Guides, VersionVerifications
UMC | KNOW MORE ABOUT VIGIBASE As well as member countries of the WHO Programme, VigiBase can be made available to anyone with a health profession degree (physician, dentist, nurse, pharmacist). If you request data, please state the purpose of your request. Each request is assessed as a securitymeasure to
UMC | WHODRUG KODA
WHODrug Koda – the coding engine. WHODrug Koda is an automated coding service custom-built by UMC. The service is specifically designed for increasing the efficiency, consistency and quality of drug coding, with the end goal of safer use of medicines. UMC recognises that the vital activity of drug coding can be both challenging and timeUMC | TRAINING
We develop and update our products with input and ideas that come directly from conversations with our customers. We discuss your wishes and requirements and do our utmost to bring you the solutions you want. We know you are busy, so we have developed a range of education and training opportunities to suit your schedule. UMC | WHAT IS A SIGNAL? A signal is essentially a hypothesis of a risk with a medicine with data and arguments that support it, derived from data from one or more of many possible sources. The evidence in a signal is not conclusive (is, in the technical sense, uncertain), and is only an early indication (preliminary), as it may change substantially over time asmore
UMC | UPPSALA MONITORING CENTREGLOBAL PHARMACOVIGILANCERESEARCH & SCIENTIFIC DEVELOPMENTEDUCATION & TRAININGWHODRUG Making medicines safer for patients. Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace. Our story. UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | ANALYTICS IN VIGILYZE IC stands for “ information component ”, which is an indicator value for disproportionate reporting when using the method for disproportionality analysis developed by UMC. As with the EBGM, PRR or ROR, this is a way to relate observed and expected values to find drug–adverse effect combinations that have been reported more oftenthan one
VIGIFLOW
Vigiflow
UMC | UPPSALA MONITORING CENTREGLOBAL PHARMACOVIGILANCERESEARCH & SCIENTIFIC DEVELOPMENTEDUCATION & TRAININGWHODRUG Making medicines safer for patients. Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace. Our story. UMC | WHODRUG INSIGHT WHODrug Insight. Our search tool gives you instant access to all of the data available in WHODrug so you can code both drug names and drug classes more efficiently. With WHODrug Insight, you save time coding and can easily find all the information you need for creating and working with medications of interest lists. We are constantlydeveloping
UMC | WHODRUG GLOBAL WHODrug Global’s standardised data makes it easier to identify drug-related problems in clinical trials and pharmacovigilance, helping you to develop safer medicines. This is because using WHODrug to code data supports more effective analysis, speeding up the regulatory submission process. WHODrug Global is also an indispensablesource when
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | VIGIBASE
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site.UMC | VIGILYZE
VigiLyze. VigiLyze enables quantitative signal detection on national, regional or global data, and lets you manage signals, document your own assessments, and read UMC’s and other NCs' signals. VigiLyze supports the entire signal detection and management process with the ability to assign and document your work within the system. UMC | LEARN MORE ABOUT WHO-ART The WHO Adverse Reaction* Terminology was developed and maintained by UMC over approximately thirty years to serve as a terminology for coding adverse reaction terms, covering most medical terms needed in adverse reaction reporting. Until 2008, when MedDRA (Medical Dictionary for Regulatory Activities) was implemented, WHO-ART was theonly
UMC | ANALYTICS IN VIGILYZE IC stands for “ information component ”, which is an indicator value for disproportionate reporting when using the method for disproportionality analysis developed by UMC. As with the EBGM, PRR or ROR, this is a way to relate observed and expected values to find drug–adverse effect combinations that have been reported more oftenthan one
VIGIFLOW
Vigiflow
UMC | ONLINE LEARNING Learn where and when it suits you. Uppsala Monitoring Centre provides pharmacovigilance and health professionals with a range of distance learning options to further their education in medicines safety. These include e-learning courses on different aspects of drug safety, distance courses in collaboration with Uppsala University, and an extensive video library on YouTube.UMC | SERVICES
VigiBase Custom Searches. For professional colleagues, UMC offers custom searches of VigiBase data. Let us know the purpose of your request and your search criteria, and we will help you find the information or the solution. A consultancy fee is charged for the service, which is waived for WHO Programme members. More about customsearches.
UMC | WHO PROGRAMME MEMBERS Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. UMC | EDUCATION & TRAINING UMC runs a two-week pharmacovigilance training course in Uppsala, Sweden, each year. We also organise courses in Asia and Latin America together with the International Society of Pharmacovigilance, and provide ad-hoc courses on request. 22nd International Pharmacovigilance Training Course. ISoPUMC | ACCESS TOOLS
Depending on your level of access click on the links below for the tools and services you need: WHODrug Insight Change Request WHODrug Koda Change Analysis Licence validation. For access managers and WHODrug delivery persons: WHODrug Access Manager WHODrug Files Download. In our User Area you will find User Guides, VersionVerifications
UMC | KNOW MORE ABOUT VIGIBASE As well as member countries of the WHO Programme, VigiBase can be made available to anyone with a health profession degree (physician, dentist, nurse, pharmacist). If you request data, please state the purpose of your request. Each request is assessed as a securitymeasure to
UMC | TRAINING
We develop and update our products with input and ideas that come directly from conversations with our customers. We discuss your wishes and requirements and do our utmost to bring you the solutions you want. We know you are busy, so we have developed a range of education and training opportunities to suit your schedule. UMC | WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING The WHO Programme for International Drug Monitoring is a group of more than 150 countries that share the vision of safer and more effective use of medicines. They work nationally and collaborate internationally to monitor and identify the harm caused by medicines, to reduce the risks to patients and to establish worldwide pharmacovigilanceUMC | WHODRUG KODA
WHODrug Koda – the coding engine. WHODrug Koda is an automated coding service custom-built by UMC. The service is specifically designed for increasing the efficiency, consistency and quality of drug coding, with the end goal of safer use of medicines. UMC recognises that the vital activity of drug coding can be both challenging and time UMC | LICENSE VALIDATION SERVICE WHODrug License Validation is a mandatory procedure that confirms the WHODrug license status of an intended collaborating partner. An organisation is not allowed to provide a partner organisation with WHODrug data or parts thereof before UMC has confirmed the existence of a valid license. WHODrug users are invited to use UMC’s web-based * Global Pharmacovigilance__*
Global Pharmacovigilance 50 years of pharmacovigilance A beginner's guide to pharmacovigilance*
WHO Programme for International Drug MonitoringBeing a member
Join the WHO Programme WHO programme membersCountry guidelines
Resources and support The story of UMC and the WHO programme*
Pharmacovigilance communications Uppsala Reports magazine Drug Safety Matters podcast#MedSafetyWeek
Take&Tell
Annie & Mac’s AdventuresDrugs and Bugs
*
Publications
UMC publications
WHO publications
Glossary
*
Conferences
WHO programme annual meetingUppsala Forum
*
VigiFlow
About VigiFlow
Training materials
Documents and news
Vaccine surveillance in VigiFlow*
COVID-19
How to report ICSRs for COVID-19 treatments How to find ICSRs related to COVID-19 in VigiLyze How to understand data on side effects * Research & Scientific Development__*
Scientific Development*
Signal detection
What is a signal?
Signal detection at UMCReview panel
Communicating signalsSignal library
*
Collaborations
Current collaborations Previous collaborations*
Scientific publications Scientific Publications LibraryScientific posters
* Education & Training__*
Education & Training International pharmacovigilance training courseISoP–UMC training
*
Online learning
E-learning in pharmacovigilance E-learning courses FAQ*
Event calendar
* WHODrug__
*
WHODrug portfolio
WHODrug Global
WHODrug Standardised Drug Groupings (SDGs)WHODrug Koda
WHODrug Cross Reference ATC 5WHODrug CRT Japan
WHODrug Vendor ProgrammeWHODrug Link Korea
*
Subscription
Subscription fees criteria WHODrug Subscription InquirySubscription Types
How to subscribe
License Validation Service WHODrug Access Manager*
Training
Online WHODrug TrainingWebinars
Videocasts
Custom training
*
Access tools
Download Area
WHODrug CAT
WHODrug Change RequestWHODrug Insight
WHODrug User Area
*
User Group Meetings
*
Dictionary data upgrading Upgrading from WHODrug Enhanced to WHODrug Global B3/C3 formats upversioning*
Documents and News
What’s New 2021
WHODrug Newsletter 2021News Archive
* VigiBase__
*
VigiBase
VigiBase: signalling harm and pointing to safer use Know more about VigiBase VigiBase in Japanese*
Services
VigiBase Custom Searches Learn more about WHO-ART*
VigiLyze
Analytics in VigiLyzevigiMethods
Quantitative COVID-19 vaccine safety surveillance with VigiLyze innear real-time
* About Us__
*
Who we are
Our story
Our vision and missionUMC Board
Governance and funding UMC Strategic Executive Team*
Careers
Students
*
Privacy policy
Cookies
Sub-processors
*
Contact us
How to get to the UMC*
Uppsala Monitoring Centre*
Search
*
Login
MAKING MEDICINES SAFER FOR PATIENTS EVERYWHERERead more about UMC
WHODRUG KODA
FIND OUT HOW OUR AI CODING ENGINE CAN EMPOWER YOUR TEAM WITH UMC KNOW-HOW AND EXPERTISELearn more
MEET THE NEW CEO
HERVÉ LE LOUËT TAKESOVER AS CEO OF UMC
Read more
MAKING MEDICINES SAFER FOR PATIENTS EVERYWHERERead more about UMC
MAKING MEDICINES SAFER FOR PATIENTS Uppsala Monitoring Centre (UMC) is an independent centre for drug safety and scientific research working for a world where the safe and effective use of medicines is commonplace.Our story
PROTECTING PATIENTS FROM HARM We collect and analyse data from most countries around the world to make sure appropriate standards and systems are in place to prevent unnecessary harm to patients_._ Find out more about global pharmacovigilance LEADING THE WAY IN DRUG SAFETY UMC pushes the boundaries of pharmacovigilance to explore the benefits and risks of medicines to help patients and clinicians make wise therapeutic decisions. Explore Research and DevelopmentWHODRUG GLOBAL
The world’s most widely consulted drug dictionary is used by the pharmaceutical industry and regulatory authorities to monitor the safety of medicines throughout their life cycle. Learn more about WHODrug WORKING FOR A BETTER WORLD In our role as a WHO Collaborating Centre, we provide training, guidance and support to countries in the WHO Programme for International Drug Monitoring. We also manage VigiBase, WHO’s database of individual case safety reports and the world’s largest repository of adverse effects from medicines. _Click on our interactive map for more information on members of theWHO programme_
{ colorAxis: { min: 1979, minColor: '#f0e7ef', maxColor: '#77216c' }, tooltip: { formatter: function () { var tooltip = '' + this.point.name + '' + this.point.category + ' since ' + this.point.value + '
'; var infoItems = this.point; if (infoItems && infoItems.length) { $.each(infoItems, function (index, item) { if(item.link) { tooltip += '' + item.name + '
'; } else { tooltip += item.name + '
'; } }) } return tooltip; }, useHTML: true }} Created with Highmaps 4.2.419602100Zoom in+Zoom out-Highcharts.com © Natural EarthCopyright (c) 2015 Highsoft AS, Based on data from
Natural Earth
_*This map is an approximation of actual country borders._ OUR WEBSITE USES COOKIES Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Your privacy is of utmost importance for us, find out more.
Remind me later Don't show me again Uppsala Monitoring Centre · About CookiesPrivacy Policy
Glossary
*
*
*
*
.
__
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0